Patents by Inventor Weikang Tao

Weikang Tao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
    Patent number: 10889569
    Abstract: A condensed ring group azacyclobutyl triazole derivative, a preparation method therefor and use thereof in medicine are provided. In particular, a condensed ring group azacyclobutyl triazole derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, use thereof as a therapeutic agent, in particular as an oxytocin antagonist, and for treating or preventing a disease or a condition that is known or can exhibit a beneficial effect of inhibiting oxytocin are provided. The definition for each substituent in general formula (I) is the same as that in the description.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 12, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Wei He, Bin Wang, Zhigao Zhang, Feng He, Weikang Tao
  • STABLE ANTI-PD-1 ANTIBODY PHARMACEUTICAL PREPARATION AND APPLICATION THEREOF IN MEDICINE
    Publication number: 20210000954
    Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further con a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, obtaining a stable injected pharmaceutical preparation.
    Type: Application
    Filed: September 2, 2020
    Publication date: January 7, 2021
    Inventors: Jie Li, Zhen Yan, Pingping Wang, Yan Fang, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL APPLICATION THEREOF
    Publication number: 20200399375
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 24, 2020
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • IL-6R ANTIBODY AND ANTIGEN BINDING FRAGMENT THEREOF AND MEDICAL USE
    Publication number: 20200369774
    Abstract: Provided in the present invention are an IL-6R antibody and antigen-binding fragment thereof. The IL-6R antibody is an alpaca-derived antibody, chimeric antibody and humanized antibody. Also provided in the present invention is the use of the antibody in the preparation of a drug for treating IL-6-related diseases.
    Type: Application
    Filed: September 12, 2018
    Publication date: November 26, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Hua Ying, Houcong Jin, Qiyue Hu, Hu Ge, Yifang Wang, Weikang Tao
  • CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
    Publication number: 20200347130
    Abstract: Provided are a CD96 antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a murine antibody, a chimeric antibody and a humanized antibody comprising the CDR region of the CD96 antibody, and a pharmaceutical composition comprising the CD96 antibody and the antigen-binding fragment thereof, and the use of same as a drug. In particular, provided is a use of a humanized CD96 antibody in the preparation of a drug for treating CD96-related diseases or conditions.
    Type: Application
    Filed: November 9, 2018
    Publication date: November 5, 2020
    Inventors: Zhuoxiao CAO, Yayuan FU, Cunjing YU, Qiyue HU, Weikang TAO
  • PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF
    Publication number: 20200339692
    Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
    Type: Application
    Filed: January 9, 2019
    Publication date: October 29, 2020
    Applicants: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xiaoling GU, Jiahua JIANG, Lei ZHANG, Qiyue HU, Jinming GU, Weikang TAO
  • PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
    Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
    Patent number: 10793643
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 6, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Shaoyu Xu, Bei Yuan, Dongbing Cui, Qiyue Hu, Lei Zhang, Zhibin Xu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
    Patent number: 10786567
    Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 29, 2020
    Assignees: Suzhou Suncediabiopharmaeuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jie Li, Zhen Yan, Pingping Wang, Yan Fang, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Deuterium Atom-Substituted Indole Formamide Derivative, Preparation Method Therefor, and Medical Applications Thereof
    Publication number: 20200277278
    Abstract: A deuterium atom-substituted indole formamide derivative, a preparation method therefor, and medical applications thereof. Specifically, the present invention relates to a deuterium atom-substituted indole formamide derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses of the derivative serving as an ROR agonist and uses of the derivative in preventing and/or treating tumors or cancers, definitions of substituent groups in general formula (I) being same as definitions in the specification.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Dong Liu, Lei Chen, Biao Lu, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • PCSK9 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USES THEREOF
    Publication number: 20200270365
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.
    Type: Application
    Filed: December 26, 2016
    Publication date: August 27, 2020
    Inventors: Xiangdong QU, Xin YE, Houcong JIN, Dongbing CUI, Qiyue HU, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • IL-5 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREFOR
    Publication number: 20200262909
    Abstract: Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 20, 2020
    Inventors: Hua Ying, Jinping Shi, Ylfang Wang, Qiyue Hu, Hu Ge, Weikang Tao
  • TIGIT ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE THEREOF
    Publication number: 20200255516
    Abstract: A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Inventors: Yayuan FU, Zhuoxiao CAO, Qiyue HU, Weikang TAO
  • OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20200199115
    Abstract: The present invention relates to an oxopicolinamide derivative, a preparationmethod therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Fanglong YANG, Weimin WANG, Xiaodong LI, Gang CHEN, Feng HE, Weikang TAO
  • METHOD FOR KNOCKING OUT TARGET GENE IN T CELL IN VITRO AND crRNA USED IN THE METHOD
    Publication number: 20200181608
    Abstract: Provided is a method for knocking out target genes in T cells in vitro based on the CRISPR-Cas9 system. Also provided are crRNAs that target the TRAC, B2M and PD1 genes, and a kit comprising sgRNA formed by linking the crRNA and tracrRNA corresponding to a Cas9 protein, the Cas9 protein, an oligo deoxyribonucleic acid (N-oligo) or a milt DNA fragment. The kit is used to knock out the TCR, B2M and/or PD1 genes in T cells. Also provided are T cells with gene knockout, obtained according to a method of the present invention and uses thereof.
    Type: Application
    Filed: June 19, 2018
    Publication date: June 11, 2020
    Inventors: Zuohan PENG, Lianjun SHEN, Weikang TAO
  • PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE
    Publication number: 20200157111
    Abstract: The present invention relates to a piperazine heteroaryl derivative, a preparation method therefor and the use of same in medicine. In particular, the present invention relates to the piperazine heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and the use of same as a capsid protein inhibitor, in particular in the prevention and/or treatment of diseases such as hepatitis B, influenza, herpes, AIDS, etc. The definitions of each group in the general formula (I) are the same as those defined in the description.
    Type: Application
    Filed: July 26, 2018
    Publication date: May 21, 2020
    Inventors: Xin LI, Wei HE, Yang CHEN, Feng HE, Weikang TAO
  • FUSION PROTEIN CONTAINING TGF-ß RECEPTOR AND MEDICINAL USES THEREOF
    Publication number: 20200157180
    Abstract: The present invention provides a fusion protein containing TGF-? receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-?RII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-? receptor, and the use thereof in the preparation of anti-cancer drug.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 21, 2020
    Inventors: Jinming GU, Xiao LUO, Weikang TAO
  • HETEROARYL-PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF
    Publication number: 20200131187
    Abstract: A heteroaryl-pyrazole derivative, and a preparation method therefor and a medical application thereof are described. Specifically, a new heteroaryl-pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, and a use of the derivative as a therapeutic agent, in particular as a TLR7 agonist, are described. The substituents in formula (I) have the same definitions as in the description.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 30, 2020
    Inventors: Guobao ZHANG, Dianqiang MA, Huiqing YUAN, Feng HE, Weikang TAO
  • INDOLE-FORMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE
    Publication number: 20200131123
    Abstract: A solid dispersion, a method for preparing same, and a solid preparation comprising the solid dispersion. The solid dispersion contains (R)-4-amino-1-(1-(but-2-ynylacyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazine-7-one or a pharmaceutically acceptable salt thereof, and a carrier material. The carrier material is selected from hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 30, 2020
    Inventors: Dong LIU, Biao LU, Wenjian QIAN, Huaide DONG, Suxing LIU, Rumin ZHANG, Feng HE, Weikang TAO
  • Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
    Patent number: 10633375
    Abstract: The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 28, 2020
    Assignees: Jinagsu Hengrui Medicine Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Weimin Wang, Xiaodong Li, Gang Chen, Feng He, Weikang Tao